Sudan Loganathan
Stock Analyst at Stephens & Co.
(1.32)
# 3,438
Out of 4,876 analysts
38
Total ratings
44.83%
Success rate
-14.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Upgrades: Overweight | $29 → $60 | $43.78 | +37.05% | 5 | Jun 24, 2025 | |
| DCTH Delcath Systems | Reiterates: Overweight | $25 | $13.97 | +79.02% | 3 | Jun 23, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Equal-Weight | $150 → $135 | $128.25 | +5.26% | 3 | Jun 3, 2025 | |
| ELEV Elevation Oncology | Downgrades: Equal-Weight | $5 | $0.38 | +1,209.76% | 4 | Mar 24, 2025 | |
| IMNM Immunome | Reiterates: Overweight | $30 | $8.98 | +234.08% | 2 | Mar 20, 2025 | |
| CPRX Catalyst Pharmaceuticals | Reiterates: Overweight | $33 | $22.03 | +49.80% | 2 | Feb 27, 2025 | |
| ADCT ADC Therapeutics | Maintains: Overweight | $6 → $8 | $2.77 | +188.81% | 2 | Feb 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $50 | $21.84 | +128.94% | 2 | Feb 14, 2025 | |
| BCYC Bicycle Therapeutics | Reiterates: Equal-Weight | $15 | $7.26 | +106.61% | 2 | Jan 22, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $31 | $11.78 | +163.16% | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $60 | $44.99 | +33.36% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.59 | +215.46% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $4 | $1.50 | +166.67% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $7.80 | +605.13% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13 | $1.19 | +992.44% | 1 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $8.72 | +1,046.79% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.22 | +800.90% | 1 | May 14, 2024 |
Exelixis
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $43.78
Upside: +37.05%
Delcath Systems
Jun 23, 2025
Reiterates: Overweight
Price Target: $25
Current: $13.97
Upside: +79.02%
Blueprint Medicines
Jun 3, 2025
Downgrades: Equal-Weight
Price Target: $150 → $135
Current: $128.25
Upside: +5.26%
Elevation Oncology
Mar 24, 2025
Downgrades: Equal-Weight
Price Target: $5
Current: $0.38
Upside: +1,209.76%
Immunome
Mar 20, 2025
Reiterates: Overweight
Price Target: $30
Current: $8.98
Upside: +234.08%
Catalyst Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $22.03
Upside: +49.80%
ADC Therapeutics
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $2.77
Upside: +188.81%
IDEAYA Biosciences
Feb 14, 2025
Reiterates: Overweight
Price Target: $50
Current: $21.84
Upside: +128.94%
Bicycle Therapeutics
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $7.26
Upside: +106.61%
Nurix Therapeutics
Jan 21, 2025
Reiterates: Overweight
Price Target: $31
Current: $11.78
Upside: +163.16%
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $44.99
Upside: +33.36%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.59
Upside: +215.46%
Nov 18, 2024
Initiates: Equal-Weight
Price Target: $4
Current: $1.50
Upside: +166.67%
Nov 18, 2024
Initiates: Overweight
Price Target: $55
Current: $7.80
Upside: +605.13%
Nov 8, 2024
Initiates: Overweight
Price Target: $13
Current: $1.19
Upside: +992.44%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $8.72
Upside: +1,046.79%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $2.22
Upside: +800.90%